Abstracts Archive - Page 1940 of 2425 - ACR Meeting Abstracts

Abstract Number: 1674 • 2014 ACR/ARHP Annual Meeting
Long-Term Efficacy of Rituximab in Systemic Sclerosis
Javier Narváez¹, Juan Jose Alegre Sancho², Ivan Castellvi³, Susana Herrera⁴, Maria Molina Molina⁵, Diego Castillo⁶, Isabel de la Morena Barrio², Montserrat Robustillo Villarino², Angels Martínez Ferrer², Desamparados Ybañez García², Elia Valls Pascual², Josep Maria LLobet³, Francisca Gil Latorre⁴ and Joan Miquel Nolla⁷, ¹Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ²Rheumatology, Hospital Universitario Dr Peset, Valencia, Spain, ³Rheumatology, Hospital de Sant Pau, Barcelona, Spain, ⁴Hospital Universitario Dr Peset, Valencia, Spain, ⁵Pneumology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Pneumology, Hospital de Sant Pau, Barcelona, Spain, ⁷Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: It has been proved in several studies with a small number of patients that Rituximab (RTX) can prevent worsening of interstitial lung disease (ILD)…
Abstract Number: 1673 • 2014 ACR/ARHP Annual Meeting
Disease Specific Quality of Life in Patients with Lupus Nephritis
Chi Chiu Mok¹, Sergio Toloza², Berna Goker³, Ann E. Clarke⁴, S. Navarra⁵, Daniel J. Wallace⁶, Michael H. Weisman⁷ and Meenakshi Jolly⁸, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Hospital San Juan Bautista, San Fernando del Valle de Catamarca, Argentina, ³Department of Internal Medicine- Rheumatology, Gazi University School of Medicine, Ankara, Turkey, ⁴Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ⁵University of Santo Tomas Hospital, Manila, Philippines, ⁶Rheumatology, Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁷Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Rheumatology, Rush University Medical Center, Chicago, IL
ACR-LN Active LN No Yes P value No Yes P value Age (yrs) 42.8 (13.6) 40.3 (13.1) 0.002 41.1…
Abstract Number: 1672 • 2014 ACR/ARHP Annual Meeting
Facilitating the Medication Decision-Making process—What Do Patients with Lupus Nephritis Say?
Ricahrd Shewchuk¹, Haiyan Qu², W. Winn Chatham², Jinoos Yazdany³, Maria Dall'era⁴ and Jasvinder A. Singh⁵, ¹University fo Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Medicine, University of California, San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵University of Alabama and VA Medical Center, Birmingham, AL
Background/Purpose: Low medication adherence in lupus nephritis puts patients at risk for poor outcomes, but to our knowledge, relatively little is known about what patients…
Abstract Number: 1671 • 2014 ACR/ARHP Annual Meeting
Renal Relapses Are Common in Lupus Nephritis
Angela Pakozdi¹, Ravindra Rajakariar², Michael Sheaff³ and Dev Pyne¹, ¹Rheumatology, Barts Health NHS Trust, London, United Kingdom, ²Renal Medicine, Barts Health NHS Trust, London, United Kingdom, ³Histopathology, Barts Health NHS Trust, London, United Kingdom
Background/Purpose Renal relapses are part of the natural history of lupus nephritis (LN) and represent a significant challenge not only because they are associated with…
Abstract Number: 1670 • 2014 ACR/ARHP Annual Meeting
Characterization of Patients with Lupus Nephritis Included in a Large Cohort from the Spanish Society of Rheumatology Registry of Patients with Systemic Lupus Erythematosus
María Galindo Izquierdo¹, Esther Rodriguez-Almaraz¹, Sabina Perez², José M. Pego-Reigosa³, Jaime Calvo-Alen⁴, Francisco Javier López-Longo⁵, Iñigo Rúa-Figueroa⁶, Alejandro Olivé⁷, Víctor Martínez Taboada⁸, Paloma Vela Casasempere⁹, Mercedes Freire¹⁰, Javier Narváez¹¹, Antonio Fernandez Nebro¹², Jose Rosas¹³, Monica Ibanez Barcelo¹⁴, Esther Uriarte¹⁵, Eva Tomero¹⁶, Antonio Zea¹⁷, Maria Loreto Horcada¹⁸, Vicente Torrente¹⁹, Ivan Castellvi²⁰, Joan Calvet²¹, Raúl Menor Almagro²², Mª Angeles Aguirre²³, Enrique Raya²⁴, Elvira Diez Alvarez²⁵, Tomás Vázquez Rodríguez²⁶, Paloma García de la Peña²⁷, Atusa Movasat²⁸, José Luis Andreu²⁹, Patricia Richi³⁰, Carlos Marras Fernandez-Cid³¹, Carlos Alberto Montilla Morales³², Blanca Hernández-Cruz³³, José Luis Marenco de la Fuente³⁴, Marian Gantes³⁵, Eduardo Ucar³⁶, Juan J. Alegre³⁷, Javier Manero³⁸, Jesús Ibañez Ruán³⁹, Manuel Rodríguez-Gómez⁴⁰, Victor Quevedo⁴¹, José Hernández Beiraín⁴² and Lucía Silva Fernández⁴³, ¹Department of Rheumatology. Hospital Universitario 12 de Octubre, Madrid, Spain, ²Sociedad Española de Reumatología, Research Unit,, Madrid, Spain, ³Instituto de Investigación Biomédica de Vigo (IBIV), Vigo, Spain, ⁴Rheumatology Division, Sierrallana Hospital, Torrelavega, Spain, ⁵Rheumatology, Hospital Gregorio Marañon, Rheumatology, Hospital Gregorio Marañon, Madrid, Spain, ⁶Rheumatology, Hospital Doctor Negrin, Las Palmas de Gran Canaria, Spain, ⁷Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ⁸Rheumatology, Marqués de Valdecilla, Santander, Spain, ⁹Hospital General de Alicante, Alicante, Spain, ¹⁰Rheumatology, Hospital Universitario Juan Canalejo, La Coruña, Spain, ¹¹Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ¹²Rheumatology, Hospital Regional Carlos Haya, Biomedical Research Institute of Malaga (IBIMA), Malaga, Spain, ¹³Rheumatology, Hospital Marina Baixa. Villajoyosa, Villajoyosa, Spain, ¹⁴H. Son Llatzer, Palma de Mallorca, Spain, ¹⁵Rheumatology, Hospital de Donosti, San Sebastian, Spain, ¹⁶Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹⁷Rheumatology, Hospital Universitario Ramon y Cajal, Madrid, Spain, ¹⁸Rheumatology, Complejo Hospitalario de Navarra, Pamplona, Spain, ¹⁹Rheumatology, Hospital Moisès Broggi, Barcelona, Spain, ²⁰Unitat de Reumatologia., Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ²¹Hospital Parc Taulí, Barcelona, Spain, ²²Rheumatology, Hospital de Jerez, Jerez de la Frontera, Spain, ²³Rheumatology, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ²⁴Rheumatology, University Hospital San Cecilio, Granada, Spain, ²⁵Rheumatology, Leon Hospital, Leon, Spain, ²⁶Rheumatology, Hospital Lucus Augusti, Lugo, Spain, ²⁷Rheumatology, Hospital Norte Sanchinarro, Madrid, Spain, ²⁸Hospital Príncipe de Asturias, Immune System Diseases/Rheumatology department, Alcalá de Henares, Madrid, Spain, ²⁹Rheumatology, Hospital Puerta de Hierro, Madrid, Spain, ³⁰Hospital Infanta Sofía, Madrid, Spain, ³¹C/ Salvia 11, H. Arrixaca, Alicante, Spain, ³²Rheumatology Department, Hospital Virgen de la Vega, Salamanca, Spain, ³³Rheumatology, University Hospital Virgen Macarena, Sevilla, Spain, ³⁴Hospital de Valme. Sevilla, Sevilla, Spain, ³⁵Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain, ³⁶Hospital de Basurto, Rheumatology, Bilbao, Spain, ³⁷Rheumatology, Hospital Universitario Dr Peset, Valencia, Spain, ³⁸Ophthalmology and Rheumatology. Hospital Miguel Servet Zaragoza, Spain, Zaragoza, Spain, ³⁹POVISA, Rheumatology, Vigo, Spain, ⁴⁰Rheumatology, Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ⁴¹Rheumatology, Hospital de Monforte, Lugo, Spain, ⁴²Rheumatology, Hospital Insular de Gran Canaria, Las palmas Gran Canarias, Spain, ⁴³Rheumatology, Hospital Universitario de Guadalajara, Guadalajara, Spain
Background/Purpose To describe the profile of patients included in RELESSER with histologically confirmed lupus nephritis (LN). Methods RELESSER is a multicentre cross-sectional study, with information…
Abstract Number: 1669 • 2014 ACR/ARHP Annual Meeting
Validation of a Machine Learning Lupus Nephritis Decision Support Tool to Predict Complete Response to Therapy
Bethany Wolf¹, John Christian Spainhour¹, John Arthur², Michael Janech², Michelle Petri³, Adnan Kiani⁴ and Jim Oates^5,6, ¹Public Health Sciences, Medical University of South Carolina, Charleston, SC, ²Medicine, Medical University of South Carolina, Charleston, SC, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴1830 E Monument St, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁶Medical Service, Ralph H. Johnson VAMC, Charleston, SC
Background/Purpose .The American College of Rheumatology treatment guidelines for lupus nephritis (LN) recommend that induction therapy be changed when response to therapy has not occurred…
Abstract Number: 1668 • 2014 ACR/ARHP Annual Meeting
Identifying Patient Perceptions of Medication Decision Making Barriers in Minorities with Lupus Nephritis
Jasvinder A. Singh¹, Haiyan Qu², Jinoos Yazdany³, W. Winn Chatham², Maria Dall'era⁴ and Ricahrd Shewchuk⁵, ¹University of Alabama and VA Medical Center, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Medicine, University of California, San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵University fo Alabama at Birmingham, Birmingham, AL
Background/Purpose: Studies suggest that adherence to medications for lupus nephritis is low. However, there are limited data available on the barriers that patients with lupus…
Abstract Number: 1667 • 2014 ACR/ARHP Annual Meeting
Probability of 3 and 6 Month Complete Response in Lupus Nephritis
Homa Timlin¹, Michelle Petri¹ and Laurence S Magder², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD

Background/Purpose: Lupus nephritis is a major cause of morbidity and mortality. The complete response rate is the most sensitive in detecting differences among therapeutic regimens.…
Abstract Number: 1666 • 2014 ACR/ARHP Annual Meeting
The Relevance of Urinary Podocyte Number and Urinary Podocalyxin Level with Response to Treatment and 1 Year Renal Prognosis in Systemic Lupus Erythematosus
Hiroshi Kajiyama¹, Keiju Hiromura², Daisuke Ikuma¹, Hidekazu Ikeuchi², Hiroyuki Kurosawa³, Yoshiaki Hirayama³, Fumio Gondaira³, Masanori Hara⁴, Yoshihisa Nojima² and Toshihide Mimura⁵, ¹Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan, ²Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan, ³Department of reagent research and development, Denka Seiken Co. Ltd., Niigata, Japan, ⁴Department of Pediatrics, Yoshida Hospital, Niigata, Japan, ⁵Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose Podocytes are glomerular visceral epithelial cells, whose number decrease due to death and/or detachment from capillary wall leads to severe proteinuria and end stage…
Abstract Number: 1665 • 2014 ACR/ARHP Annual Meeting
Efficacy Versus Safety of Prednisone in Lupus Nephritis Since 1988
Tanmayee Bichile¹, Laurence S Magder² and Michelle Petri³, ¹Rehumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose Morbidity and damage due to prednisone use in the treatment of SLE is recognized, but prednisone has been a requisite of lupus nephritis induction…
Abstract Number: 1664 • 2014 ACR/ARHP Annual Meeting
Novel Risk Factors for Systemic Lupus Erythematosus (SLE) Flares in Patients with End-Stage Renal Disease: Is SLE in Patients with End-Stage Renal Disease a “sleeping beauty”?
Jorge Alcocer-Varela¹, Mariana Quintanar², Javier Merayo-Chalico³, Ana Barrera-Vargas¹ and Diana Gómez-Martín¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose Renal involvement in systemic lupus erythematosus (SLE) is frequent, and a high percentage of patients (~15%) develop end-stage renal disease (ESRD) even with optimal…
Abstract Number: 1663 • 2014 ACR/ARHP Annual Meeting
Influence of Ethnicity on Efficacy of Current Immunosuppressive Protocols in Proliferative Lupus Nephritis
Angela Pakozdi¹, Ravindra Rajakariar², Michael Sheaff³ and Dev Pyne¹, ¹Rheumatology, Barts Health NHS Trust, London, United Kingdom, ²Renal Medicine, Barts Health NHS Trust, London, United Kingdom, ³Histopathology, Barts Health NHS Trust, London, United Kingdom
Background/Purpose Lupus nephritis (LN) is a major complication of systemic lupus erythematous (SLE) and prevalence is estimated to be 50-60%. Recently, variable responses to induction…
Abstract Number: 1682 • 2014 ACR/ARHP Annual Meeting
Mycophenolate Mofetil Versus Azathioprine in Scleroderma-Associated Interstitial Lung Disease: Results from the Australian Scleroderma Cohort Study
Claire Owen¹, Gene Ngian², Kathleen Elford², Owen Moore³, Mandy Nikpour³, Wendy Stevens³, Susanna Proudman⁴, Janet Roddy⁵, Jane Zochling⁶, Catherine Hill⁷, Peter Nash⁸, Allan Sturgess⁹ and Joanne Sahhar², ¹Rheumatology, Monash Health, Melbourne, Australia, ²Monash Health, Melbourne, Australia, ³St Vincent's Hospital, Melbourne, Australia, ⁴Royal Adelaide Hospital, Adelaide, Australia, ⁵Royal Perth Hospital, Perth, Australia, ⁶Department of Rheumatology, Menzies Research Institute Tasmania, Hobart, TAS, Australia, ⁷Queen Elizabeth Hospital, Adelaide, Australia, ⁸Sunshine Coast Rheumatology, Maroochydore, Australia, ⁹The St George Hospital, Sydney, Australia
Background/Purpose: Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is common and when progressive, associated with significant morbidity and mortality. Cyclophosphamide is frequently used as first line…
Abstract Number: 1681 • 2014 ACR/ARHP Annual Meeting
Heart Transplantation in 6 Patients with Systemic Sclerosis and a Primary Cardiac Involvement
Alena Ikic¹, Emmanuel Chatelus², Eric Epailly³, Hélène Kremer³, Jean Sibilia², Jacques Gottenberg⁴, Sabine Pattier⁵, Erwan Flecher⁶, Céline Goeminne⁷ and Thierry Martin¹, ¹Strasbourg University Hospital, Strasbourg, France, ²Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ³Cardiology, Strasbourg University Hospital, Strasbourg, France, ⁴Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁵Cardiology, Nantes University Hospital, Nantes, France, ⁶Cardiac Surgey, Rennes University Hospital, Rennes, France, ⁷Cardiology, Lille University Hospital, Lille, France
Background/Purpose: There is no specific treatment for primary cardiac involvement in SSc. Even if heart transplantation is an option, only 1 case have been reported1.…
Abstract Number: 1680 • 2014 ACR/ARHP Annual Meeting
an Indirect Comparisons Analysis of Medications Used for Treatment of Raynaud’s Phenomenon
Sampath Manickam¹, Elie Donath², Sandeep Dayanand³ and Jonathan Greer⁴, ¹University of Miami Palm Beach Internal Medicine, West Palm Beach, FL, ²Internal Medicine, University of Miami Miller School of Medicine Palm Beach Regional Campus, Atlantis, FL, ³University of Miami Palm Beach Internal medicine, West palm beach, FL, ⁴Arthritis & Rheumatology Associates, Boynton Beach, FL
An Indirect Comparisons Analysis of Medications used for treatment of Raynaud’s phenomenonBackground/Purpose: There are several pharmacological treatments used for treatment of Raynaud’s phenomenon: calcium channel…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].